Antibody

Laboratory mouse
#Ageing #Antibody #Duke-NUS Medical School #Healthspan #Imperial College London #Medical Research Council Laboratory of Medical Science #Mouse models

Anti-IL-11 drug extends lifespan by over 20% in mice

Scientists have discovered that ‘switching off’ protein interleukin 11 (IL-11) can significantly increase the healthy lifespan of mice by almost 25%. The scientists at the Medical Research Council Laboratory of Medical Science (MRC LMS) and Imperial College London, working with colleagues at Duke-NUS Medical School in… Read More

#Editor's Choice #News

Business financing
#AltruBio #Antibody #Financing #Phase II trial #Ulcerative colitis (UC)

$225m to advance novel immune checkpoint enhancer programme

AltruBio has closed an oversubscribed Series B financing of up to $225 million, which will be used to advance the clinical development of the first-in-class, novel immune checkpoint enhancer (ICE) PSGL-1 agonist antibody, ALTB-268. The funds will be used to support ongoing and planned Phase II clinical trials in ulcerative… Read More

#Business & Investment #News

Cancer cells
#Antibody #Brain cancer #Cancer research #CAR-T #CRISPR #Oncology

2023 cancer research highlights: Drug development at its best

Lu Rahman selects some of the year’s interesting and noteworthy advances in cancer research drug discovery and development. As always, a year within cancer drug discovery and development brings with it significant breakthroughs, and 2023 has been no exception. Figures from the Amercian Cancer Society1 state that “a little over… Read More

#Cancer Research #Exclusive Content

Gastric cancer
#Antibody #FDA #Gastrointestinal #Oncology #Phase III trial #Stomach cancer #Transcenta

Antibody for gastric cancer progresses to Phase III trials

The US Food and Drug Administration (FDA) has granted clearance to Transcenta to proceed with its TranStar 301 global Phase III pivotal trial of Osemitamab (TST001) for gastric cancer. The trial will investigate the drug in combination with Nivolumab and chemotherapy as a first-line treatment in patients with HER2-negative, CLDN18.2… Read More

#Cancer Research #News #Regulatory

Lungs
#Antibody #Cancer research #Cancer vaccine #IO Biotech #Lung cancer #Merck #Oncology #Phase II trial

IO Biotech announces data for therapeutic cancer vaccine

IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win technology platform, has announced data from a pre-defined interim analysis related to the lung cohort of the Phase II basket trial (IOB-022/KN-D38) with IO102-IO103 in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy as… Read More

#Cancer Research #News

#Antibody #Antivirals #Immunology / Virology & Vaccines #Neurodegenerative disorders #Neuroscience #Oncology

New DDW Highlights episode out now

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Diana Spencer has chosen news stories this week which all discuss pre-clinical research studies… Read More

#News

#Antibody #Antivirals #Immunology / Virology & Vaccines #Neurodegenerative disorders #Neuroscience #Oncology

This week in drug discovery (14-18 August)  

News round-up for 14-18 August by DDW Digital Content Editor Diana Spencer. My chosen news stories this week all discuss pre-clinical research studies that could have a huge impact on our therapeutic approach to several hard-to-treat diseases, helping to overcome drug-resistance and make treatments more targeted… Read More

#News

Antibody
#Acute inflammatory conditions #Antibody #Autoimmune disease #Biologics

Novel antibody displays potent anti-inflammatory activity

Researchers have shown that a novel antibody has greater activity and potentially fewer side effects than existing biological therapies for conditions such as rheumatoid arthritis (RA), psoriasis, and inflammatory bowel disease (IBD). The antibody, called Ab-IPL-IL-17, targets a specific section of signalling proteins IL-17A and IL-17F… Read More

#News

IgE antibodies
#Antibody #Cancer research #Cancer Research UK #Epsilogen #King's College London #Oncology #Phase I trial

New class of antibody cancer drug shows promise

A Cancer Research UK-funded clinical trial has shown, for the first time, that a new class of antibody could benefit cancer patients whose existing treatments have stopped working. The Phase I clinical trial, sponsored and managed by Cancer Research UK’s Centre for Drug Development, tested whether… Read More

#Cancer Research #News

Genetic engineering concept with medication capsule with human brain diagram at programming language background
#Antibody #Drug discovery #Immuno-oncology #Therapeutic Antibodies #Therapeutics

DDW Summer 2023 issue out now

The Summer 2023 issue of Drug Discovery World Magazine is out now and includes an exclusive guide on Therapeutic Antibodies.  Featuring a Therapeutic Spotlight on Immuno-oncology, the magazine is available to download free here and read for free on the DDW App.  You can also… Read More

#News

Peanuts
#Allergy #Antibodies #Antibody #IgGenix #Monoclonal antibodies

Could a monoclonal antibody treat peanut allergy?

IgGenix has made advances towards a peanut allergy therapeutic based on IgG4 monoclonal antibodies. The company’s research data was presented during the 2023 European Academy of Allergy and Clinical Immunology (EAACI) Congress, in Hamburg, Germany. The data shows that nearly all peanut-specific IgE antibodies… Read More

#News

Subcutaneous injection
#Antibody #Autoimmune disease #Drug delivery #FDA #Halozyme #Phase III trial

FDA approves subcutaneous injectable for myasthenia gravis

The US Food and Drug Administration (FDA) has given approval to Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) injection with Enhanze for subcutaneous (SC) use for the treatment of generalised myasthenia gravis (gMG). The treatment is approved in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. Vyvgart Hytrulo is a… Read More

#News #Regulatory

Laboratory research
#Antibody #ASCO #Cancer research #Clinical trials #Immunotherapy #Janssen #Oncology #T cell activation

Janssen updates ASCO 2023 on oncology pipeline

Janssen has presented new data from across its oncology pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Talquetamab Talquetamab is an investigational GPRC5D-directed bispecific antibody currently in clinical development. Updated results from the Phase II MonumenTAL-1 study show that… Read More

#Cancer Research #News #Trending News

#Alzheimer's #Antibody #Eisai #MHRA #Neurodegenerative disorders #Phase II trial

Eisai applies for MHRA approval for lecanemab in Alzheimer’s

Eisai has submitted a marketing authorisation application (MAA) for lecanemab, an investigational anti-amyloid beta (Aβ) protofibril antibody to the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain. The MAA is for the treatment of early Alzheimer’s disease (AD) (mild cognitive impairment due to AD and mild AD dementia)… Read More

#News #Regulatory

Myeloma cells
#AACR 2023 #Antibody #Cancer research #Immunotherapy #Myeloma #Oncology #T cell activation

Bispecific antibody has 90% response rate in multiple myeloma

Patients with relapsed or refractory multiple myeloma who were treated with the two highest doses of REGN5459, a bispecific antibody targeting BCMA and CD3, experienced a 90.5% overall response rate. This is according to results of a Phase I/II clinical trial presented at the AACR Annual… Read More

#Cancer Research #News #Trending News

PD-L1 antibody
#Antibody #Cancer research #Collaboration #Merck #Oncology #Pfizer

Merck buys full rights to cancer drug Bavencio from Pfizer

Merck has bought the exclusive worldwide rights to develop, manufacture and commercialise anti PD-L1 antibody Bavencio (avelumab) from Pfizer. Merck will take full control of the global commercialisation of Bavencio through its affiliate Ares Trading. The transaction has also ended a long-term collaboration between Merck and Pfizer. The current profit… Read More

#Business & Investment #News